The estimated Net Worth of Saiid Zarrabian is at least $947 Thousand dollars as of 14 November 2017. Mr. Zarrabian owns over 60,900 units of DelMar Pharmaceuticals stock worth over $7,906 and over the last 11 years he sold DMPI stock worth over $0. In addition, he makes $939,035 as President, Chief Executive Officer, and Director at DelMar Pharmaceuticals.
Saiid has made over 3 trades of the DelMar Pharmaceuticals stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 60,900 units of DMPI stock worth $49,938 on 14 November 2017.
The largest trade he's ever made was buying 60,900 units of DelMar Pharmaceuticals stock on 14 November 2017 worth over $49,938. On average, Saiid trades about 4,399 units every 86 days since 2013. As of 14 November 2017 he still owns at least 5,900 units of DelMar Pharmaceuticals stock.
You can see the complete history of Mr. Zarrabian stock trades at the bottom of the page.
Saiid Zarrabian serves as President, Chief Executive Officer, Director of the Company. From 2014 to 2015 he operated a private personal business. Since October 2016, Mr. Zarrabian has served as an advisor to Redline Capital Partners, S.A., a Luxembourg based investment firm. From 2012 to 2014 he served as Chairman and member of the Board of La Jolla Pharmaceutical Company during which time the company transitioned from an OTC listed company to a Nasdaq listed company. From 2012 to 2013 he served as President of the Protein Production Division of Intrexon Corporation, a synthetic biology company. He has also previously served as CEO and member of the Board of Cyntellect, Inc., a stem cell processing and visualization Instrumentation company until its sale in 2012, as President and COO of Senomyx, Inc., a company focused on discovery and commercialization of new flavor ingredients, and as COO of Pharmacopeia, Inc., a former publicly-traded provider of combinatorial chemistry discovery services and compounds, where he also served as President & COO of its MSI Division. In addition, Mr. Zarrabian has served on numerous private and public company boards, including at Immune Therapeutics, Inc., Exemplar Pharma, LLC, Ambit Biosciences Corporation, eMolecules, Inc., and Penwest Pharmaceuticals CO. His other experience includes COO at Molecular Simulations, COO of Symbolics, Inc., and as R&D Director at Computervision, Inc. Mr. Zarrabian’s business executive knowledge and experience qualify him to serve on our Board of Directors.
As the President, Chief Executive Officer, and Director of DelMar Pharmaceuticals, the total compensation of Saiid Zarrabian at DelMar Pharmaceuticals is $939,035. There are no executives at DelMar Pharmaceuticals getting paid more.
Saiid Zarrabian is 67, he's been the President, Chief Executive Officer, and Director of DelMar Pharmaceuticals since 2018. There are 1 older and 5 younger executives at DelMar Pharmaceuticals. The oldest executive at DelMar Pharmaceuticals, Inc. is Dennis Brown, 71, who is the Chief Scientific Officer.
Saiid's mailing address filed with the SEC is 12707 HIGH BLUFF DR., SUITE 200, , SAN DIEGO, CA, 92130.
Over the last 11 years, insiders at DelMar Pharmaceuticals have traded over $104,000 worth of DelMar Pharmaceuticals stock and bought 663,835 units worth $651,854 . The most active insiders traders include John K Bell, Robert Hoffman, and Jeffrey Bacha. On average, DelMar Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $20,766. The most recent stock trade was executed by John K Bell on 13 September 2019, trading 35,000 units of DMPI stock currently worth $23,800.
DelMar Pharmaceuticals, Inc. is a clinical and biopharmaceutical company, which focuses on the development and commercialization of new cancer therapies. It pipeline includes the VAL-083. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
DelMar Pharmaceuticals executives and other stock owners filed with the SEC include: